H. Conseil-de-la-santé-publique, Evaluation du plan cancer 2003-2007 : Rapport final Ministère de la santé et des sports, p.495, 2009.

. Ministère-de-la-santé,-de-la-jeunesse, des sports et de la vie associative, Décret n°2005- 1023 du 24 août 2005 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné à l'article L, du code de la sécurité sociale, pp.162-184, 2005.

L. Ministère-de and . Santé, de la jeunesse, des sports et de la vie associative, Circulaire n°DHOS/E2/DSS/1C, 2006.

. Legifrance, Arrêté du 18 février 2009 pris pour l'application de l'article L. 162-22-7-2 du code de la sécurité sociale 2009 [cité; Disponible à

D. Theis, V. Gilleron, and A. M. Schott, [An overview of the 2001-2002 cancer activity in the 30 French Regional and University Hospitals, based on PMSI data]. Bull Cancer, pp.94-915, 2007.

A. Belot, P. Grosclaude, and N. Bossard, Cancer incidence and mortality in France over the period 1980???2005, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.3, pp.159-175, 2008.
DOI : 10.1016/j.respe.2008.03.117

URL : https://hal.archives-ouvertes.fr/inserm-00338335

O. Mondiale-de and L. Santé, Classification statistique internationale des maladies et des problèmes de santé connexes : CIM-10 Méthodologie générale d'élaboration des protocoles thérapeutiques hors GHS. 2007. p. 5. 11. Institut National du Cancer, Référentiels de bon usage hors GHS : Cancers bronchiques et mesotheliomes pleuraux malin. 2009. p. 59. 12. Institut National du Cancer, Référentiels de bon usage hors GHS : Cancers digestifs, Genève. 167. 10. AFSSAPS/HAS/INCa 53. 13. Institut National du Cancer, Référentiels de bon usage hors GHS : Oncologie thoracique, p.53, 1995.

J. J. Vredenburgh, A. Desjardins, and J. E. Herndon, Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.25, issue.30, pp.25-4722, 2007.
DOI : 10.1200/JCO.2007.12.2440

A. Alsace, Site Parhtage, Janvier, 2009.

L. Remontet, N. Mitton, and C. M. Couris, Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, European Journal of Epidemiology, vol.26, issue.10, pp.681-688, 2008.
DOI : 10.1201/9781420010138

URL : https://hal.archives-ouvertes.fr/inserm-00338952

I. Debrix, M. Sitbon, and A. Khalil, Référentiel de bon usage and Thésaurus national de cancérologie digestive: analysis of non conform prescriptions in Tenon hospital, Bulletin du cancer, vol.96, issue.2, pp.147-154, 2009.

R. M. Zuniga, R. Torcuator, and R. Jain, Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan, Journal of Neuro-Oncology, vol.82, issue.3, pp.91-329, 2009.
DOI : 10.1016/j.brainresrev.2004.03.001

T. Caruba, . Pharmd, and P. H. Cottu, Gemcitabine?Oxaliplatin Combination in Heavily Pretreated Metastatic Breast Cancer: A Pilot Study on 43 Patients, The Breast Journal, vol.23, issue.2, pp.165-171, 2007.
DOI : 10.1093/annonc/mdh351

N. Girard and F. Mornex, Stage IIIB non-small cell lung cancer. Optimization of radiotherapy in lung cancer: some interesting questions to be solved, Rev Mal Respir, vol.235, pp.16-61, 2006.

N. Girard and F. Mornex, Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last! Bull Cancer, pp.94-127, 2007.

K. D. Miller, L. I. Chap, and F. A. Holmes, Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer, Journal of Clinical Oncology, vol.23, issue.4, pp.792-799, 2005.
DOI : 10.1200/JCO.2005.05.098

J. P. Micha, B. H. Goldstein, and M. A. Rettenmaier, A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer, International Journal of Gynecological Cancer, vol.17, issue.4, pp.771-776, 2007.
DOI : 10.1111/j.1525-1438.2007.00886.x

R. A. Burger, M. W. Sill, and B. J. Monk, Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.25, issue.33, pp.25-5165, 2007.
DOI : 10.1200/JCO.2007.11.5345

S. A. Cannistra, U. A. Matulonis, and R. T. Penson, Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer, Journal of Clinical Oncology, vol.25, issue.33, pp.25-5180, 2007.
DOI : 10.1200/JCO.2007.12.0782

J. D. Wright, A. Hagemann, and J. S. Rader, Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma, Cancer, vol.5, issue.1, pp.83-89, 2006.
DOI : 10.1016/S0002-9440(10)64467-7

J. C. Chura, K. Van-iseghem, L. S. Downs, and . Jr, Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer???, Gynecologic Oncology, vol.107, issue.2
DOI : 10.1016/j.ygyno.2007.07.017